Seyed Abbas Tabatabaee Yazdi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Seyed Abbas Tabatabaee Yazdi has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Abbas Abdollahi
Endoscopic and Minimally Invasive Surgery Research Center Mashhad University of Medical Sciences Mashhad Iran
1 shared publication - Ali Mehri
Endoscopic and Minimally Invasive Surgery Research Center Mashhad University of Medical Sciences Mashhad Iran
1 shared publication - Bibi Marjan Razavi
Department of Pharmacodynamics and Toxicology, School of Pharmacy Mashhad University of Medical Sciences Mashhad Iran
1 shared publication - Farhad Eisvand
Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
1 shared publication - Fatemeh Masoudi Nasab
Department of Pathology, Faculty of Medicine Mashhad University of Medical Sciences Mashhad Iran
1 shared publication - Hossein Hosseinzadeh
Department of Pharmacodynamics and Toxicology, School of Pharmacy Mashhad University of Medical Sciences Mashhad Iran
1 shared publication
Latest Publications
- Open Access
- 4 October 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (10) , e73653
Tumefactive Crohn's Disease Presenting as Multiple Colonic Mass‐Like Lesions Mimicking Colon Carcinoma in a Middle‐Aged Man: A Case Report
This case report highlights the importance of considering tumefactive Crohn's disease in the differential diagnosis of inflammatory bowel disease presenting with a colonic mass. This condition can resemble colorectal carcinoma in endoscopic and radiologic assessments, making histopathological examination critical for accurate diagnosis, which impacts surveillance protocols and medical management.
- 4 October 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (10) , e73653
Open AccessTumefactive Crohn's Disease Presenting as Multiple Colonic Mass‐Like Lesions Mimicking Colon Carcinoma in a Middle‐Aged Man: A Case Report
This case report highlights the importance of considering tumefactive Crohn's disease in the differential diagnosis of inflammatory bowel disease presenting with a colonic mass. This condition can resemble colorectal carcinoma in endoscopic and radiologic assessments, making histopathological examination critical for accurate diagnosis, which impacts surveillance protocols and medical management.
- 27 December 2021
- Published by Wiley in Phytotherapy Research
- Vol. 36 (1) , 506-524
Cardioprotective effects of alpha‐mangostin on doxorubicin‐induced cardiotoxicity in rats
The main adverse effect of doxorubicin is cardiotoxicity. Oxidative stress and apoptosis induction have been suggested as mechanisms involved in its cardiotoxicity. In this study, cardioprotective effects of alpha‐mangostin against doxorubicin‐induced cardiotoxicity have been investigated in rats. Forty‐two rats were divided as follows: Control, doxorubicin (2 mg/kg every 48 hr), alpha‐mangostin (200 mg/kg), alpha‐mangostin (50, 100, 200 mg/kg) + doxorubicin (2 mg/kg every 48 hr), and vitamin E (200 IU/kg) + doxorubicin (2 mg/kg every 48 hr). Alpha‐mangostin was administered by gavage for 19 days, while doxorubicin (12 days) and vitamin E (19 days) were injected intraperitoneally. Doxorubicin decreased heart rate, increased electrocardiogram signal components duration and reduced systolic and diastolic arterial blood pressure, and caused histological damage in the heart of rats. Doxorubicin decreased heart weight and heart/body weight ratio, as well as elevated creatine phosphokinase isoenzyme and lactate dehydrogenase. Doxorubicin increased malondialdehyde, inflammatory biomarkers, and caspases 3 and 9 and decreased reduced glutathione content in heart tissue but co‐administration of alpha‐mangostin (100 mg/kg) restored all doxorubicin toxic effects. Results show that alpha‐mangostin has protective effects against doxorubicin‐induced cardiotoxicity by antioxidant, antiinflammatory, and antiapoptotic effects that may ameliorate doxorubicin cardiotoxicity in human chemotherapy without reduction in its anticancer effect.
- 27 December 2021
- Published by Wiley in Phytotherapy Research
- Vol. 36 (1) , 506-524
Cardioprotective effects of alpha‐mangostin on doxorubicin‐induced cardiotoxicity in rats
The main adverse effect of doxorubicin is cardiotoxicity. Oxidative stress and apoptosis induction have been suggested as mechanisms involved in its cardiotoxicity. In this study, cardioprotective effects of alpha‐mangostin against doxorubicin‐induced cardiotoxicity have been investigated in rats. Forty‐two rats were divided as follows: Control, doxorubicin (2 mg/kg every 48 hr), alpha‐mangostin (200 mg/kg), alpha‐mangostin (50, 100, 200 mg/kg) + doxorubicin (2 mg/kg every 48 hr), and vitamin E (200 IU/kg) + doxorubicin (2 mg/kg every 48 hr). Alpha‐mangostin was administered by gavage for 19 days, while doxorubicin (12 days) and vitamin E (19 days) were injected intraperitoneally. Doxorubicin decreased heart rate, increased electrocardiogram signal components duration and reduced systolic and diastolic arterial blood pressure, and caused histological damage in the heart of rats. Doxorubicin decreased heart weight and heart/body weight ratio, as well as elevated creatine phosphokinase isoenzyme and lactate dehydrogenase. Doxorubicin increased malondialdehyde, inflammatory biomarkers, and caspases 3 and 9 and decreased reduced glutathione content in heart tissue but co‐administration of alpha‐mangostin (100 mg/kg) restored all doxorubicin toxic effects. Results show that alpha‐mangostin has protective effects against doxorubicin‐induced cardiotoxicity by antioxidant, antiinflammatory, and antiapoptotic effects that may ameliorate doxorubicin cardiotoxicity in human chemotherapy without reduction in its anticancer effect.